Cargando…

ET-9 Development of photosensitive antibodies for near-infrared light immunotherapy targeting EGFR and IL13Rα2 of malignant gliomas and investigation of their photodynamic cytotoxic activity in vitro

Introduction: Near-Infrared Photoimmunotherapy (NIR-PIT) is a recently developed hybrid cancer therapy based on photodynamic cytotoxicity and anti-tumor immunopotentiation, utilizing a photosensitive antibody drug (PSAD). A global Phase III trial of NIR-PIT with an anti-EGFR-PSAD in patients with re...

Descripción completa

Detalles Bibliográficos
Autores principales: Nonoguchi, Naosuke, Kambara, Akihiro, Kimura, Seigo, Kawabata, Shinji, Yagi, Ryokichi, Ikeda, Naokado, Furuse, Motomasa, Wanibuchi, Masahiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8648211/
http://dx.doi.org/10.1093/noajnl/vdab159.019
_version_ 1784610757967609856
author Nonoguchi, Naosuke
Kambara, Akihiro
Kimura, Seigo
Kawabata, Shinji
Yagi, Ryokichi
Ikeda, Naokado
Furuse, Motomasa
Wanibuchi, Masahiko
author_facet Nonoguchi, Naosuke
Kambara, Akihiro
Kimura, Seigo
Kawabata, Shinji
Yagi, Ryokichi
Ikeda, Naokado
Furuse, Motomasa
Wanibuchi, Masahiko
author_sort Nonoguchi, Naosuke
collection PubMed
description Introduction: Near-Infrared Photoimmunotherapy (NIR-PIT) is a recently developed hybrid cancer therapy based on photodynamic cytotoxicity and anti-tumor immunopotentiation, utilizing a photosensitive antibody drug (PSAD). A global Phase III trial of NIR-PIT with an anti-EGFR-PSAD in patients with recurrent head and neck squamous cell carcinoma (HNSCC) is already underway, and NIR-PIT is expected to have therapeutic applications also in malignant gliomas. Methods: In this study, monoclonal antibodies to EGFR and IL13Rα2 were conjugated to the photosensitive dye IRDye700DX (IR700) to produce PSADs (EGFR-Ab/IR700 and IL13Rα2-Ab/IR700) and in vitro PDT assays using these PSADs were performed on four human glioma cell lines (U87MG, U251, U138, A172).Five groups were studied: EGFR-Ab/IR700 monotherapy: 5 μg/ml or 10 μg/ml, IL13Rα2-Ab/IR700 monotherapy: 5 μg/ml or 10 μg/ml, and EGFR-Ab/IR700: 5 μg/ml + IL13Rα2-Ab/IR700: 5 μg/ml combination therapy. The cytotoxic activity of each group was compared after irradiation with 690 nm light at 16 J/cm2. Results: Significantly higher cytotoxic activity was observed in all four glioma cell lines when EGFR-Ab/IR700 and IL13Rα2-Ab/IR700 were used in combination at 5 μg/ml each, than when each PSAD was treated with a doubled dose (10 μg/ml).Conclusion: Malignant gliomas show extensive cellular heterogeneity with diverse expression of cell surface antigens. The present results suggest that a therapeutic strategy using several different photosensitive antibodies simultaneously may lead to the release of tumor antigens from a greater number of tumor cells, resulting in a more efficient host immune response for therapeutic purposes.
format Online
Article
Text
id pubmed-8648211
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-86482112021-12-07 ET-9 Development of photosensitive antibodies for near-infrared light immunotherapy targeting EGFR and IL13Rα2 of malignant gliomas and investigation of their photodynamic cytotoxic activity in vitro Nonoguchi, Naosuke Kambara, Akihiro Kimura, Seigo Kawabata, Shinji Yagi, Ryokichi Ikeda, Naokado Furuse, Motomasa Wanibuchi, Masahiko Neurooncol Adv Supplement Abstracts Introduction: Near-Infrared Photoimmunotherapy (NIR-PIT) is a recently developed hybrid cancer therapy based on photodynamic cytotoxicity and anti-tumor immunopotentiation, utilizing a photosensitive antibody drug (PSAD). A global Phase III trial of NIR-PIT with an anti-EGFR-PSAD in patients with recurrent head and neck squamous cell carcinoma (HNSCC) is already underway, and NIR-PIT is expected to have therapeutic applications also in malignant gliomas. Methods: In this study, monoclonal antibodies to EGFR and IL13Rα2 were conjugated to the photosensitive dye IRDye700DX (IR700) to produce PSADs (EGFR-Ab/IR700 and IL13Rα2-Ab/IR700) and in vitro PDT assays using these PSADs were performed on four human glioma cell lines (U87MG, U251, U138, A172).Five groups were studied: EGFR-Ab/IR700 monotherapy: 5 μg/ml or 10 μg/ml, IL13Rα2-Ab/IR700 monotherapy: 5 μg/ml or 10 μg/ml, and EGFR-Ab/IR700: 5 μg/ml + IL13Rα2-Ab/IR700: 5 μg/ml combination therapy. The cytotoxic activity of each group was compared after irradiation with 690 nm light at 16 J/cm2. Results: Significantly higher cytotoxic activity was observed in all four glioma cell lines when EGFR-Ab/IR700 and IL13Rα2-Ab/IR700 were used in combination at 5 μg/ml each, than when each PSAD was treated with a doubled dose (10 μg/ml).Conclusion: Malignant gliomas show extensive cellular heterogeneity with diverse expression of cell surface antigens. The present results suggest that a therapeutic strategy using several different photosensitive antibodies simultaneously may lead to the release of tumor antigens from a greater number of tumor cells, resulting in a more efficient host immune response for therapeutic purposes. Oxford University Press 2021-12-06 /pmc/articles/PMC8648211/ http://dx.doi.org/10.1093/noajnl/vdab159.019 Text en © The Author(s) 2021. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Supplement Abstracts
Nonoguchi, Naosuke
Kambara, Akihiro
Kimura, Seigo
Kawabata, Shinji
Yagi, Ryokichi
Ikeda, Naokado
Furuse, Motomasa
Wanibuchi, Masahiko
ET-9 Development of photosensitive antibodies for near-infrared light immunotherapy targeting EGFR and IL13Rα2 of malignant gliomas and investigation of their photodynamic cytotoxic activity in vitro
title ET-9 Development of photosensitive antibodies for near-infrared light immunotherapy targeting EGFR and IL13Rα2 of malignant gliomas and investigation of their photodynamic cytotoxic activity in vitro
title_full ET-9 Development of photosensitive antibodies for near-infrared light immunotherapy targeting EGFR and IL13Rα2 of malignant gliomas and investigation of their photodynamic cytotoxic activity in vitro
title_fullStr ET-9 Development of photosensitive antibodies for near-infrared light immunotherapy targeting EGFR and IL13Rα2 of malignant gliomas and investigation of their photodynamic cytotoxic activity in vitro
title_full_unstemmed ET-9 Development of photosensitive antibodies for near-infrared light immunotherapy targeting EGFR and IL13Rα2 of malignant gliomas and investigation of their photodynamic cytotoxic activity in vitro
title_short ET-9 Development of photosensitive antibodies for near-infrared light immunotherapy targeting EGFR and IL13Rα2 of malignant gliomas and investigation of their photodynamic cytotoxic activity in vitro
title_sort et-9 development of photosensitive antibodies for near-infrared light immunotherapy targeting egfr and il13rα2 of malignant gliomas and investigation of their photodynamic cytotoxic activity in vitro
topic Supplement Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8648211/
http://dx.doi.org/10.1093/noajnl/vdab159.019
work_keys_str_mv AT nonoguchinaosuke et9developmentofphotosensitiveantibodiesfornearinfraredlightimmunotherapytargetingegfrandil13ra2ofmalignantgliomasandinvestigationoftheirphotodynamiccytotoxicactivityinvitro
AT kambaraakihiro et9developmentofphotosensitiveantibodiesfornearinfraredlightimmunotherapytargetingegfrandil13ra2ofmalignantgliomasandinvestigationoftheirphotodynamiccytotoxicactivityinvitro
AT kimuraseigo et9developmentofphotosensitiveantibodiesfornearinfraredlightimmunotherapytargetingegfrandil13ra2ofmalignantgliomasandinvestigationoftheirphotodynamiccytotoxicactivityinvitro
AT kawabatashinji et9developmentofphotosensitiveantibodiesfornearinfraredlightimmunotherapytargetingegfrandil13ra2ofmalignantgliomasandinvestigationoftheirphotodynamiccytotoxicactivityinvitro
AT yagiryokichi et9developmentofphotosensitiveantibodiesfornearinfraredlightimmunotherapytargetingegfrandil13ra2ofmalignantgliomasandinvestigationoftheirphotodynamiccytotoxicactivityinvitro
AT ikedanaokado et9developmentofphotosensitiveantibodiesfornearinfraredlightimmunotherapytargetingegfrandil13ra2ofmalignantgliomasandinvestigationoftheirphotodynamiccytotoxicactivityinvitro
AT furusemotomasa et9developmentofphotosensitiveantibodiesfornearinfraredlightimmunotherapytargetingegfrandil13ra2ofmalignantgliomasandinvestigationoftheirphotodynamiccytotoxicactivityinvitro
AT wanibuchimasahiko et9developmentofphotosensitiveantibodiesfornearinfraredlightimmunotherapytargetingegfrandil13ra2ofmalignantgliomasandinvestigationoftheirphotodynamiccytotoxicactivityinvitro